Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
about
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerBisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceLow-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancerProbenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cellsRole of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates.Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialA randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study.Oral bisphosphonate use and risk of postmenopausal endometrial cancer.Therapeutic targets for bone metastases in breast cancer.Current approaches to bone-targeted therapy in genitourinary malignanciesBisphosphonates as potential adjuvants for patients with cancers of the digestive system.Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles.Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?Bisphosphonamidate clodronate prodrug exhibits selective cytotoxic activity against melanoma cell lines.Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.Bisphosphonates as antimyeloma drugs.Denosumab and the current status of bone-modifying drugs in breast cancer.Pharmacodynamics of bisphosphonates in arthritis.The Electroporation as a Tool for Studying the Role of Plasma Membrane in the Mechanism of Cytotoxicity of Bisphosphonates and Menadione.Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells.Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasisSevere toxicity with a generic formulation of zoledronic Acid: a case report.Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results.Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.Inhibitory effects of CP on the growth of human gastric adenocarcinoma BGC-823 tumours in nude mice.Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
P2860
Q26746212-535EDE25-0034-42D1-85A8-2DD817141215Q26795493-C31B69DE-D954-4AB9-B21C-615D36A10DF5Q27306861-8FA07A78-DDFD-496C-BF2B-E49F511395F1Q28087676-74ABC40D-51A6-43D1-B6DC-56CC1A491D11Q34077388-B013DF60-172D-4FE5-B237-1834CD0B7C14Q34653709-99922238-5D81-4246-A93A-C50C1127DF12Q34945422-25B43A74-0866-49E5-902B-F94001EB8603Q34967135-84EEE86D-CB9F-41DF-B185-0DE28C9B206AQ35091107-B36C606E-7B9A-47EB-8F19-EC33315FC1CCQ35141814-2DAF8D2B-AAF2-4A1E-9FC3-3F044AD91781Q35190713-0F3E6D10-F7DD-4295-B5AF-DC2CE63564D6Q35215054-D911F98E-779A-44EF-89A5-A5351A8F9378Q35558919-BBE3B397-9B24-43E8-B893-B1211B6E9ADBQ36231718-C8D13A83-0C02-4D33-87C4-7D35E8A2A545Q36471673-ECBE8EF1-8218-493F-86E0-FC4218931B4EQ36505441-F82E8B7E-BC2B-439E-8403-AD15D712327CQ36520822-D7000D7E-7AC3-42F9-A7D1-4A100B8F2378Q36883879-795FF040-B6F5-43BA-B999-E8CCE3A874D8Q37043903-50A883B2-2365-4CD1-B2D0-3C148284DA35Q37187646-35B8236B-F322-4937-874D-8FF962BE6A90Q37418042-0BBC765B-5696-427B-9F4A-813BCFB9972CQ37623726-F665DFD7-5288-40A9-A0E7-23481FF5A9FEQ37703392-EB00CCCC-10FC-4E9A-9FC5-36058F487995Q37946695-416660B6-E806-49A9-B361-8C83BA44F98CQ37965768-2F210B6E-E097-44FD-BA34-54C4F01A42C7Q37973356-5022B823-52EF-46B7-8F23-61677378E228Q38780783-7DEDFADA-3D24-4879-91EE-33D7CE5D3376Q38798990-791274AD-9A60-4763-B284-6EFE0817A4E6Q39453295-C7116DF3-0085-4B8D-84B2-1B217F3C0929Q39550317-52A2A184-31EC-4971-91FE-A8A321A060BFQ39830389-A6E53953-AE03-4702-81B2-1D2E6C1DDBC8Q41975333-C69AFDA4-EEBF-4CDB-9BA6-65FA4FE34B8EQ44538922-03FDE565-B65F-457B-8DE5-40760A2376FBQ46277856-9551AF0F-8B7E-406A-A5B6-C44DD90A653EQ47712068-E789B812-5B78-423C-9C27-858B30435E6AQ48059346-2879F1AC-CD28-4F7F-A02F-5DEFEF5D83BCQ50266714-D827B417-AC64-4FC8-894F-DE9E65C2B5C2Q51736129-CA099442-1480-4339-8093-D201057323A8Q53098071-503E2C15-1B20-42D1-BEAD-77D2F731425CQ55008337-9D9C05EA-4819-4050-A7C8-43C4B4FBB833
P2860
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
@en
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
@nl
type
label
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
@en
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
@nl
prefLabel
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
@en
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
@nl
P1433
P1476
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class
@en
P2093
Philippe Clézardin
P356
10.1016/J.BONE.2010.07.016
P577
2010-07-22T00:00:00Z